Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD

 Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD

Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD

Shots:

  • Regenxbio has reported that the ATMOSPHERE trial evaluating RGX-314 is active and patient screening is ongoing. The study will enroll 300 patients across two RGX-314 dose arms vs ranibizumab, with anticipated initiation of patients dosing in Q1’21
  • The second trial is expected to be similar in design to ATMOSPHERE with its expected initiation in H1’21. The company expects to submit a BLA based on these trials in 2024
  • The company has completed enrollment of patients in Cohort 1 of the P-II AAVIATE study for wet AMD. Moreover, Regenxbio reported a new program RGX-202 for DMD with its expected IND filing in mid-2021

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: BioHealth Capital Region

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post